TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease
Brief Summary: This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.


Options:
A: Arm Label: Spirometry and a brief advice to quit smoking; Type: EXPERIMENTAL; Interventions: Behavioral: Spirometry and a brief advice to quit smoking | Arm Label: Brief advice to quit smoking; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief advice to quit smoking | Intervention Type: BEHAVIORAL; Name: Spirometry and a brief advice to quit smoking; Assigned to Arm(s): Spirometry and a brief advice to quit smoking | Intervention Type: BEHAVIORAL; Name: Brief advice to quit smoking; Assigned to Arm(s): Brief advice to quit smoking
B: Arm Label: Champix plus counselling; Type: EXPERIMENTAL; Interventions: Drug: Champix | Arm Label: counselling alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Counselling alone | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Champix plus counselling | Intervention Type: BEHAVIORAL; Name: Counselling alone; Assigned to Arm(s): counselling alone
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease
Brief Summary: This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
B: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease
Brief Summary: This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease
Brief Summary: This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
B: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline
C: Arm Label: Bupropion and Weight Concerns intervention; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: weight concerns intervention | Arm Label: Placebo and Weight Concerns; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Behavioral: weight concerns intervention | Arm Label: Bupropion and standard smoking cessation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: smoking cessation intervention | Arm Label: Placebo and standard smoking cessation; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: smoking cessation intervention | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Bupropion and standard smoking cessation | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Weight Concerns, Placebo and standard smoking cessation | Intervention Type: BEHAVIORAL; Name: weight concerns intervention; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Placebo and Weight Concerns | Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): Bupropion and standard smoking cessation, Placebo and standard smoking cessation
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Counseling | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: BEHAVIORAL; Name: Counseling; Assigned to Arm(s): Placebo, Varenicline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease
Brief Summary: This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placeo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: St. John's Wort-900 mg/day; Type: EXPERIMENTAL; Interventions: Drug: St. John's Wort-900 mg/day | Arm Label: St. John's Wort-1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: St. John's Wort-1800mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placeo | Intervention Type: DRUG; Name: St. John's Wort-900 mg/day; Assigned to Arm(s): St. John's Wort-900 mg/day | Intervention Type: DRUG; Name: St. John's Wort-1800mg/day; Assigned to Arm(s): St. John's Wort-1800 mg/day
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
D: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease
Brief Summary: This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bupropion + Naltrexone | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bupropion + Naltrexone; Assigned to Arm(s): 2
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmacist-delivered group program for smoking cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Brief standard care session for smoking cessation delivered over the telephone | Intervention Type: OTHER; Name: Pharmacist-delivered group program for smoking cessation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Brief standard care session for smoking cessation delivered over the telephone; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Peer-Enhanced Intervention to Support Teen Weight Loss
Brief Summary: The purpose of this study is to determine whether adding a peer-based intervention based on an outward bound model is more effective than a standard behavioral weight intervention for helping adolescents lose weight.


Options:
A: Arm Label: CBT with peer-enhanced activities; Type: EXPERIMENTAL; Interventions: Behavioral: CBT with peer-enhanced activities | Arm Label: CBT with supervised aerobic exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT with supervised aerobic exercise | Intervention Type: BEHAVIORAL; Name: CBT with peer-enhanced activities; Assigned to Arm(s): CBT with peer-enhanced activities | Intervention Type: BEHAVIORAL; Name: CBT with supervised aerobic exercise; Assigned to Arm(s): CBT with supervised aerobic exercise
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction of sugar-sweetened beverage consumption | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reduction of sugar-sweetened beverage consumption; Assigned to Arm(s): 1
C: Arm Label: W82GO; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: W82GO | Arm Label: Smartphone; Type: EXPERIMENTAL; Interventions: Device: smartphone application | Intervention Type: BEHAVIORAL; Name: W82GO; Assigned to Arm(s): W82GO | Intervention Type: DEVICE; Name: smartphone application; Assigned to Arm(s): Smartphone
D: Intervention Type: BEHAVIORAL; Name: Low glycemic index diet; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development and Evaluation of Support Groups for Patients With Mild Cognitive Impairment and Their Partners
Brief Summary: This study aims at developing and evaluating a support group program for patients with mild cognitive impairment (MCI) and their partners. These patients have defective memory function but are not demented. However, there is an increased chance of developing dementia in the near future; 10-15% per year for MCI patients, in contrast to 1-2% per year for healthy elderly persons. For the patients and their caregivers this means that they are confronted with feelings of uncertainty and fear towards the future. They also have many questions about how to improve their memory problems and how to cope with other changes or consequences.

The purpose of the support group program is to improve coping skills and facilitate adaptation to the impairments, in order to reduce anxiety or depression and strengthen feelings of competence in patients and their partners.


Options:
A: Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2 Brief Supportive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Supportive Therapy | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: BEHAVIORAL; Name: Brief Supportive Therapy; Assigned to Arm(s): 2 Brief Supportive Therapy
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to interest | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to function | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Activity matched to both interest and function | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Activity matched to interest; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Activity matched to function; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Activity matched to both interest and function; Assigned to Arm(s): 3
C: Intervention Type: BEHAVIORAL; Name: support groups; Assigned to Arm(s): N/A
D: Arm Label: Behavior Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation (BA) | Arm Label: Supportive Therapy (ST); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Supportive Therapy (ST) | Intervention Type: BEHAVIORAL; Name: Behavioral Activation (BA); Assigned to Arm(s): Behavior Activation | Intervention Type: BEHAVIORAL; Name: Supportive Therapy (ST); Assigned to Arm(s): Supportive Therapy (ST)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration, a Randomized Controlled Trial Comparing Anticoagulation With Citrate to the Low Molecular Weight Heparin Nadroparin
Brief Summary: Severely ill patients admitted to the intensive care unit may develop an acute failure of kidney function. To bridge the period to recovery, renal function is temporarily replaced by continuous venovenous hemofiltration (CVVH). To prevent clotting of the hemofiltration circuit, heparin is generally used, providing anticoagulation in the circuit and the patient. As a result, bleeding complications may occur, necessitating the transfusion of blood. Anticoagulation of the circuit can also be obtained with the use of tri-sodium citrate, which provides anticoagulation of the circuit without affecting coagulation in the patient and thus without increasing his/her risk of bleeding. The use of citrate may however cause metabolic complications.

Primary aim of the present study is to show in a larger group of intensive care patients whether the use of regional anticoagulation with citrate is safe compared to systemic anticoagulation with the low molecular weight heparin nadroparin.


Options:
A: Arm Label: SLED; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Arm Label: CVVHD; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Intervention Type: PROCEDURE; Name: Renal replacement therapy; Assigned to Arm(s): CVVHD, SLED
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Continuous venvenous hemofiltration (CVVH) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous venovenous hemodialysis (CVVHD) | Intervention Type: DEVICE; Name: Continuous venvenous hemofiltration (CVVH); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Continuous venovenous hemodialysis (CVVHD); Assigned to Arm(s): 2
C: Arm Label: citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: trisodium citrate | Arm Label: nadroparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: nadroparin | Intervention Type: DRUG; Name: trisodium citrate; Assigned to Arm(s): citrate | Intervention Type: DRUG; Name: nadroparin; Assigned to Arm(s): nadroparin
D: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration, a Randomized Controlled Trial Comparing Anticoagulation With Citrate to the Low Molecular Weight Heparin Nadroparin
Brief Summary: Severely ill patients admitted to the intensive care unit may develop an acute failure of kidney function. To bridge the period to recovery, renal function is temporarily replaced by continuous venovenous hemofiltration (CVVH). To prevent clotting of the hemofiltration circuit, heparin is generally used, providing anticoagulation in the circuit and the patient. As a result, bleeding complications may occur, necessitating the transfusion of blood. Anticoagulation of the circuit can also be obtained with the use of tri-sodium citrate, which provides anticoagulation of the circuit without affecting coagulation in the patient and thus without increasing his/her risk of bleeding. The use of citrate may however cause metabolic complications.

Primary aim of the present study is to show in a larger group of intensive care patients whether the use of regional anticoagulation with citrate is safe compared to systemic anticoagulation with the low molecular weight heparin nadroparin.


Options:
A: Arm Label: citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: trisodium citrate | Arm Label: nadroparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: nadroparin | Intervention Type: DRUG; Name: trisodium citrate; Assigned to Arm(s): citrate | Intervention Type: DRUG; Name: nadroparin; Assigned to Arm(s): nadroparin
B: Arm Label: High citrate group; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Arm Label: Low citrate group; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): High citrate group, Low citrate group
C: Arm Label: 1 prostacyclin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: prostacyclin | Arm Label: 2 heparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: heparin | Intervention Type: DRUG; Name: prostacyclin; Assigned to Arm(s): 1 prostacyclin group | Intervention Type: DRUG; Name: heparin; Assigned to Arm(s): 2 heparin group
D: Arm Label: heparinized saline priming group; Type: EXPERIMENTAL; Interventions: Drug: heparinized saline priming group | Arm Label: nafamostat infusion group after heparinized saline priming; Type: ACTIVE_COMPARATOR; Interventions: Drug: nafamostat infusion after heparinized saline priming | Intervention Type: DRUG; Name: heparinized saline priming group; Assigned to Arm(s): heparinized saline priming group | Intervention Type: DRUG; Name: nafamostat infusion after heparinized saline priming; Assigned to Arm(s): nafamostat infusion group after heparinized saline priming

Answer: A